Humanized IgG1 anti-CD20 monoclonal antibody that binds CD20 on B cells (pre-B to mature, not plasma cells) and depletes them via ADCC, CDC, and apoptosis; diminishes B-cell–driven adaptive immune activity. Approved for RRMS.
Humanized IgG1 monoclonal antibody targeting CD20 on pre-B to mature B cells (sparing plasma cells), depleting them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis to suppress B cell–mediated adaptive immunity.
YES
DIRECT
Anti-CD20 IgG1 binds CD20 on B cells and induces Fc-mediated ADCC by NK cells/macrophages and complement-dependent cytotoxicity, with some apoptosis, depleting CD20+ cells.
Personalized cellular immunotherapy using patient-derived tumor-resident T cells (primarily CD8+ and CD4+) expanded ex vivo and reinfused as a single IV infusion (e.g., 2.0×10^7 cells/kg) to recognize tumor/neoantigens via TCR–MHC interactions and mediate cytotoxicity through perforin/granzyme and cytokine release.
Autologous tumor-resident T cells (CD8+/CD4+) expanded ex vivo and reinfused; they recognize patient-specific tumor/neoantigens via native TCR–MHC I/II interactions and mediate cytotoxicity through perforin/granzyme release and cytokine secretion (e.g., IFN-γ, TNF-α), enhancing antitumor immunity within the tumor microenvironment.
YES
DIRECT
TILs recognize PRAME-derived peptide epitopes presented on HLA via native TCRs, triggering cytolytic degranulation (perforin/granzymes) and death receptor/cytokine-mediated killing of the target cell.
Polyclonal rabbit antithymocyte globulin; IV antibody biologic that depletes T cells via complement-mediated lysis, opsonization, and apoptosis, and can modulate/deplete other leukocyte subsets.
Polyclonal rabbit antithymocyte immunoglobulin that binds multiple T‑cell surface antigens, causing complement-mediated lysis, opsonization/ADCC, and apoptosis to deplete T lymphocytes; can also modulate or deplete other leukocyte subsets, resulting in immunosuppression.
YES
DIRECT
Polyclonal antibodies in RATG bind CD2 on T cells and trigger complement-dependent lysis and Fc-mediated ADCC/opsonization, and can induce apoptosis, depleting CD2+ cells.
Polyclonal rabbit antithymocyte globulin; IV antibody biologic that depletes T cells via complement-mediated lysis, opsonization, and apoptosis, and can modulate/deplete other leukocyte subsets.
Polyclonal rabbit antithymocyte immunoglobulin that binds multiple T‑cell surface antigens, causing complement-mediated lysis, opsonization/ADCC, and apoptosis to deplete T lymphocytes; can also modulate or deplete other leukocyte subsets, resulting in immunosuppression.
YES
DIRECT
Polyclonal rabbit ATG binds CD3 on T cells and triggers complement-dependent lysis, Fc-mediated ADCC/opsonization, and apoptosis, depleting CD3+ cells.
Polyclonal rabbit antithymocyte globulin; IV antibody biologic that depletes T cells via complement-mediated lysis, opsonization, and apoptosis, and can modulate/deplete other leukocyte subsets.
Polyclonal rabbit antithymocyte immunoglobulin that binds multiple T‑cell surface antigens, causing complement-mediated lysis, opsonization/ADCC, and apoptosis to deplete T lymphocytes; can also modulate or deplete other leukocyte subsets, resulting in immunosuppression.
YES
DIRECT
Antithymocyte polyclonal IgG binds CD25 on T cells and triggers complement-dependent lysis and Fc-mediated ADCC/opsonophagocytosis, leading to lysis/apoptosis of CD25+ cells.